Heterodimeric antibodies that bind CD3 and GPC3
Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
1. A bispecific antibody that binds human CD3 and human GPC3 comprising:
a) a first monomer comprising the amino acid sequence set forth in SEQ ID NO: 414;
b) a second monomer comprising the amino acid sequence set forth in SEQ ID NO: 415; and
c) a third monomer comprising the amino acid sequence set forth in SEQ ID NO: 416.
2. A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claim 1 ;
b) a second nucleic acid encoding said second monomer claim 1 ; and
c) a third nucleic acid encoding said third monomer of claim 1 .
3. An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid of claim 2 ;
b) a second expression vector comprising said second nucleic acid of claim 2 ; and
c) a third expression vector comprising said third nucleic acid of claim 2 .
4. A host cell comprising said expression vector composition of claim 3 .
5. A method of making a bispecific antibody that binds human CD3 and human GPC3 comprising culturing said host cell of claim 4 under conditions wherein said bispecific antibody is expressed, and recovering said bispecific antibody.